33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • DNMT3A mutations in the hematopoietic system promote colitis-associated colon cancer: A model of clonal hematopoiesis in solid tumors
    Meeting Abstract

    Feng, Y.; Newsome, R.; Robinson, T.; Bowman, R. L.; Zuniga, A.; Hall, K.; Bernsten, C.; Shabashvili, D.; Krajcik, K.; Gunaratne, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Effect of brentuximab vedotin addition to chemotherapy and prognostic factors in patients with relapsed/refractory hodgkin lymphoma: A large multi-trial analysis based on individual patient data
    Meeting Abstract

    Driessen, J.; de Wit, F.; Herrera, A. F.; Zinzani, P. L. L.; LaCasce, A. S.; Moskowitz, C. H.; Garcia-Sanz, R.; Cole, P. D.; Fuchs, M.; Mueller, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Deep phenotyping reveals expansion of T follicular regulatory cells and triple positive (CTLA4, TIGIT, PD1) exhausted effector memory T cells characterizing the immunosuppressive microenvironment in follicular lymphoma
    Meeting Abstract

    El Daker, S.; Freeman, D.; Baik, J.; Zhu, M.; Chattopadhyay, P.; Roshal, M.; Dogan, A.; Galera, P.
    Blood (2021)

    Fulltext@MSK | Save
  • Entospletinib (ENTO) and decitabine (DEC) combination therapy in older newly diagnosed (ND) acute myeloid leukemia (AML) patients with mutant TP53 or complex karyotype is associated with poor response and survival: A phase 2 sub-study of the Beat AML Master Trial
    Meeting Abstract

    Duong, V. H.; Ruppert, A. S.; Mims, A. S.; Borate, U.; Stein, E. M.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W. G.; Arellano, M. L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC)
    Meeting Abstract

    DiNardo, C. D.; Dohner, H.; Zeidan, A. M.; Schuh, A. C.; Vyas, P.; Stein, E. M.; Wei, A. H.; de Botton, S.; Chen, C.; Lord-Bessen, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Single cell ATAC lineage deconvolution reveals overlapping subclones in epigenetically distinct AML samples
    Meeting Abstract

    Dilip, D.; Koche, R.; Menghrajani, K.; Melnick, A.; Elemento, O.; Levine, R. L.; Glass, J. L.
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical predictors of outcome in adult patients with acute leukemias and myelodysplastic syndrome and COVID-19 Infection: Report from the American Society of Hematology Research Collaborative (ASH RC) data hub
    Meeting Abstract

    Desai, P.; Goldberg, A. D.; Anderson, K. C.; Narendra, V.; Neuberg, D. S.; Radhakrishnan, V.; Redd, R. A.; Roboz, G. J.; Sehn, L. H.; Sekeres, M. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Molecular and genetic characterization of tumor samples from patients with relapsed or refractory follicular lymphoma identifies factors influencing response to tazemetostat
    Meeting Abstract

    Dave, S. S.; Happ, L.; Yasso, C.; Salles, G.; Batlevi, C. L.; Phillips, T.; Yang, J.; Adib, D.; Michaud, N. R.; Morschhauser, F.
    Blood (2021)

    Fulltext@MSK | Save
  • MAJIC: A phase 3 prospective, multicenter, randomized, open-label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
    Meeting Abstract

    Davids, M. S.; Mato, A. R.; Hum, J.; Wargo, S.; Emeribe, U.; Shahkarami, M.; Sokolowski, K.; Biondo, J. M. L.; Abhyankar, S.; Hermann, R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Post hoc analysis of responses to ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) by baseline BCR-ABL1 level and baseline mutation status in the OPTIC trial
    Meeting Abstract

    Deininger, M. W.; Apperley, J. F.; Arthur, C. K.; Chuah, C.; Hochhaus, A.; De Lavallade, H.; Lipton, J. H.; Lomaia, E.; McCloskey, J. K.; Maness, L. J.; more...
    Blood (2021)

    Fulltext@MSK | Save